cyrilzakka/clinical-trials huggingface dataset:
Effects of Hip Strength Training and Neuromuscular Electrical Stimulation on Functional Ankle Instability

The goal of this clinical trial is to compare the effects of two methods of elevating hip muscle strength on functional ankle instability(FAI). . The main question\[s\] it aims to answer are:

* Whether hip strength training and neuromuscular electrical stimulation of the gluteal muscles, respectively, based on conventional ankle training improves dysfunction in patients with FAI?
* Is there a difference in the efficacy of the above two interventions for FAI?

Participants will be randomly divided into 3 groups (Experimental Group A, Experimental Group B and Control Group) to receive the intervention for 6 weeks. The Control Group will undergo conventional ankle interventions such as peri-ankle muscle strength training and ankle balance training; Experimental Group A will undergo hip muscle strength training based on the conventional training; and Experimental Group B will perform neuromuscular electrical stimulation of hip abductors and hip extensors based on the conventional training. Researchers will compare the three groups to see changes in hip muscle strength, lower extremity muscle activation, ankle muscle strength, proprioception, dynamic and static balance, and self-reported ankle function.

Eligibility Criteria:
Inclusion Criteria:

* History of at least one acute ankle sprain one year ago, accompanied by symptoms such as pain, swelling, and inability to participate in daily activities for more than one day.
* Unilateral ankle sprains and or instability felt at least twice during the past year.
* Last ankle sprain occurred greater than or equal to 1 month from the start of the experiment.
* Cumberland Ankle Instability Tool (CAIT) score less than or equal to 27 points,
* The results of Medial Talar Tilt Test and Anterior Draw Test are negative.
* Body Mass Index （BMI）ranges from 18 to 25.

Exclusion Criteria:

* History of lower extremity surgery or fracture.
* History of brain injury or neurological disorders.
* Acute injury to musculoskeletal structures of other joints of the lower extremities within 1 month, affecting joint integrity and function.
* Participated in lower extremity rehabilitation or systematic athletic training after injury.
Resting Metabolic Rate Reliability

This research is being conducted to study the reliability of a method used to measure resting metabolic rate, or how much energy a person expends while at rest.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 - 65 years old
* BMI of 19 - 40 kg/m2
* Women must not be pregnant or planning to become pregnant

Exclusion Criteria:

* Age less than 18 or greater than 65
* BMI less than 19 or greater than 40
* Tobacco use
* Taking medications that affect metabolic rate (unless weight stable for past 3 months)
* Any disease that affects the metabolic rate
A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease

The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease

Chronic pelvic pain is the major sequela of pelvic inflammatory disease and it's a common, burdensome, and costly condition that disproportionately affects women. This multicenter, randomized, double-blind, dose-parallel, placebo-controlled phase III clinical trial is designed to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease. In this trial, 414 subjects were enrolled and randomized to either "Jincaopian Tablets" group, or the "placebo" group in a 2:1 ratio. The treatment period is 12 weeks and the follow-up period is 4 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;
* The average VAS score of pain in the week before enrollment is ≥4;
* The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);
* Women aged 18 to 50 (including 18 and 50) with a history of sexual life;
* Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.

Exclusion Criteria:

* Pelvic inflammatory disease (acute attack);
* Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 6 months after the trial;
* Previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;
* Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis;
* Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms;
* Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages;
* Received related treatment or took drugs with similar functions and indications within 14 days before the introduction;
* Liver function: ALT or AST\>1.5 times the upper limit of normal value；Renal function：Scr\>1.0 times the upper limit of normal value;
* Serum CA125 and erythrocyte sedimentation \> 1.1 times the upper limit of normal value.
* Combined with serious cardiovascular, cerebrovascular, hematopoietic system and other serious diseases;
* Have an allergic history to the experimental drug;
* Have a long history of alcoholism or drug abuse;
* Intellectual disabilities or mental disorders;
* Participated in other clinical trials within the past 3 months;
* The investigator believes that it is not suitable to participate in this clinical trial.
Two Different Preparations of Sevoflurane in Induction

In our study we aim to study the effects of two preparations of Sevoflurane in vital capacity rapid inhalation induction.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing abdominal surgery

Exclusion Criteria:

* Patients with any cardiovascular or respiratory disease, usage of any kind of sedative drug, expected airway difficulty and obese patients (BMI\>35) will be excluded from the study
Immersive Versus Passive Virtual Reality on Upper Limb Pain and Range of Motion in Pediatric Burn

The purpose of the present study was to declare the difference between using immersive virtual reality vs passive virtual reality on pain management and improvement of ROM post physiotherapy exercise and mobilization sessions in pediatric burn patients.

Burn injuries are devastating and cause long-term damage to health. Thermal injuries, caused by hot liquids, solids, or fire, account for the majority of these injuries. Around 11 million burn cases occur annually worldwide. Rehabilitation aims to improve joint range od motion and control pain. Nonpharmocologic strategies like hypnosis and VR systems have shown promise in pain control. Multidisciplinary interventions from psychologists, physiotherapists, and pain management specialists can contribute to patient recovery. VR offers a holistic care device for pediatric burn patients.

Eligibility Criteria:
Inclusion Criteria:

1. Sixty patients have 2nd degree thermal burn injury, from both genders their ages will be ranged from 7 - 17 years old.
2. They will be diagnosed by their physicians with 2nd degree thermal burn injury affecting upper limbs and referred for physical therapy management .
3. TBSA calculated up to 9 for one upper limb.
4. The patients will be in the acute stage post burn injury; the duration of burn will be 3 weeks post injury.
5. Medically and psychologically stable patients

Exclusion Criteria:

The potential participants will be excluded if they meet one of the following criteria:

1. Cardiac diseases.
2. Hand Burn
3. Exposed tendons.
4. Patients who suffer from skin diseases, diabetes, varicose veins, and peripheral vascular diseases.
5. Patients with life threatening disorders as renal failure, myocardial infarction or other similar diseases.
6. Patients with facial burn.
7. Patients will have an inability to tolerate visual stimulation (e.g., susceptibility to migraines aggravated by light) or inability to tolerate the head mounted display (e.g., sensitivity to touch around the face and head).
8. Patients with visual or auditory disorders.
9. Patients with unstable fractures.
10. Central Nervous System (CNS) problems.
11. Patients with medical red flags as severe psychiatric disorder or cognitive deficits .
12. Medically unstable and uncooperative patients.
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.

The total duration of the study was 18 weeks, comprising a 2-week screening period and a 16-week treatment period. Patients meeting the eligibility criteria for provisional enrollment received the study drug for the screening period (solifenacin) at the same dose as that before the start of the study (2.5 or 5 mg), once daily after breakfast orally for 2 weeks. After the screening period, patients meeting the eligibility criteria for formal enrollment received the study drugs for the treatment period (solifenacin 2.5 or 5 mg and mirabegron 25 mg), once daily after breakfast orally for 16 weeks. Mirabegron dose could be increased to 50 mg at week 8 visit if the patients met all of the following criteria: (1) had an inadequate response to mirabegron at the dose of 25 mg; (2) was judged by the investigator or coinvestigator to have no safety concerns; and (3) agreed to increase the dose.

Eligibility Criteria:
Inclusion Criteria:

* Female: postmenopausal OAB outpatient
* Male: OAB outpatient who did not wish to have children at all
* Patient had been treated with solifenacin at a stable dose once daily for at least 4 weeks prior to the study
* Patient had a total OAB symptom score (OABSS ) score of ≥3 points and a Question 3 score ≥2 points

Exclusion Criteria:

* Patient had a residual urine volume of ≥100 mL or a maximum flow rate \<5 mL/s, or patients with benign prostatic hyperplasia, or lower urinary tract obstruction
* Patient had serious heart disease (myocardial infarction, cardiac failure, uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver disease, kidney disease, immunological disease, lung disease, etc. or patient had malignant tumor (except for malignant tumor that has not been treated for at least 5 y before the start of the screening period with no risk of recurrence)
* Patient had received surgical therapy that may affect the urinary tract function within 24 weeks before the start of the screening period
Change in Muscle Volume in Patients With Unilateral Femoro-acetabular Impingement Syndrome After Hip Arthroscopy

The purpose of this study was to investigate the change in muscle volume around the hip in patients with unilateral femoro-acetabular impingement (FAI) after arthroscopy.

We performed a retrospective review of magnetic resonance imaging (MRI) data of FAI patients who underwent hip arthroscopy between January 1, 2016, and July 1, 2018. "Image J" with an embedded region-of-interest (ROI) tool was used to calculate the cross-sectional area (CSA) of muscles on MRI. Wilcoxon signed-rank test was used to determine the differences between preoperative and postperative hip muscle CSA. The correlations of change in muscle CSA with age, gender, BMI, pain level, preoperative symptom duration, and multiple validated patient-reported outcomes were also analyzed with a spearman rank correlation test.

Eligibility Criteria:
Inclusion Criteria:

* (1) Age 18-50 years; (2) symptoms, physical examination, imaging evidence in accordance with FAI; (3) symptoms that were not alleviated by nonsurgical treatment; (4) the operation is performed by the same senior operator.

Exclusion Criteria:

* (1) bilateral symptoms; (2) revision surgery; (3) advanced osteoarthritis; (4) acetabular dysplasia; (5) history of hip and knee joint disease and operation; (6) osteonecrosis of hip; (7) sacroiliac joint disease
Evive Health Randomized Controlled Trials

The mailer will encourage those who are due for mammograms, colonoscopies, blood pressure or cholesterol tests to receive the appropriate test. This particular mailer will only be sent to Evive clients in need to the test in question. The research will examine differences in follow-through on this recommendation among the targeted population over the 3-12 month period following the mailing as a function of experimental condition.


Eligibility Criteria:
Inclusion Criteria:

* Employee at partner corporation
* Due for mammogram, colonoscopy, blood pressure or cholesterol test

Exclusion Criteria:

* Already received mammogram, colonoscopy, blood pressure or cholesterol test
Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs

This is a single-center, observational clinical study that plans to recruit 64 ovarian cancer patients within one year. The purpose of this study is to evaluate the consistency and accuracy of the organoid model derived from patients with ovarian cancer and the patient's clinical medication, so as to predict the clinical efficacy of anti-cancer drugs


Eligibility Criteria:
Inclusion Criteria:

- Patients with ovarian cancer who are diagnosed as ovarian cancer by tissue and/or cytology and need neoadjuvant, adjuvant or standard treatment Age 18-75 years old (including 18 years old and 75 years old) It is clear that there are measurable lesions (according to RECIST1.1)

Exclusion Criteria:

- Patients with concurrent radiotherapy and chemotherapy, less than half a year of radiotherapy, or patients undergoing radiotherapy during the study period During the study period, patients need other tumor treatment methods such as surgery, intervention, radiofrequency ablation, etc.

Immune deficiency or severe bone marrow suppression The patient has severe liver and kidney disease, cardiovascular disease, blood disease, etc.

Illegal use of drugs or chronic alcohol abuse or total daily alcohol intake\> 50 g/d Lack of autonomy, unable to walk, or unable to participate in the 6-month follow-up
Isometric Abdominal and Specific Gluteus Medius Work in Soccer Players

The problems of lack of lumbo-pelvic stability, as well as weakness or mobile restriction of the adductor muscles, may be the origin of lower limb injuries. Both intrinsic and extrinsic factors are key in the probability of suffering an imbalance. A protocol of abdominal isometric strength, accompanied by specific exercises of the gluteus medius, can be useful in order to prevent such dysfunctions.

The objective is to compare the efficacy of abdominal isometric work against the specific work of gluteus medius in the improvement of lumbo-pelvic stability and strength and elasticity of the adductor muscles.

Study design. Randomized, longitudinal, experimental, prospective, multicentre and single-blind clinical trial. It will take place at the facilities of the Soccer Club Fuenlabrada S. A. D. and the European University of Madrid.

The subjects will be randomly divided into two groups: control group and experimental group. The intervention period will last eight weeks, performing 2 weekly sessions, of approximately 20 minutes (depending on the group to which each subject belongs). The variables to be evaluated before and after the intervention will be the lumbo-pelvic stability and the strength and elasticity of the adductor muscles. For the statistical analysis, the SPSS program version 19.0 will be used.

It is expected to find how gluteal work produces improvements in lumbo-pelvic stability, as well as an increase in strength and adduction elasticity.

Each session will last 20 minutes, taking place during 2 days a week, in a period of 8 weeks. The intervention will be carried out at the beginning of the training session. This intervention consists of an abdominal work protocol, and a gluteal work protocol added to the previous protocol, performed by the control group and the experimental group, respectively.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 35 years
* Federated in the Royal Football Federation of Madrid currently and with a minimum of 4 years
* Without any previous pathology or during the experimental period
* Signed the informed consent

Exclusion Criteria:

* Not have current or previous pathology in any region of the lower limb during the last 6 months
* Inability or inability to comply with the demands of the study in terms of follow-up or problems of involvement
* Players under pharmacological treatment or exercising a physiotherapy treatment parallel to the development of the study
Ultra Dual-Energy X-ray Absorptiometry (DXA): Accurate and Precise Quantitative Multi-compartment Body Composition

The central hypothesis is that the combination of measurements from 3D optical scans with standard DXA scans can be used to calculate 4 unique body composition compartments: water, fat, protein, mineral. This is significant because it will allow for accurate assessment of adiposity and functional protein status independent of hydration. The hypothesis is based on preliminary data collected demonstrating the use of thickness and dual energy X-ray measurements to calculate three-compartment breast composition.

This is a cross-sectional comparative technology study using a sample of convenience stratified by age, sex, and BMI. Following consent, each participant will undergo:

* 6 DXA whole body scans. The primary measure is bone mineral mass and body volume. DXA body volume is measured using equations from previous work that relate the fat, lean, and bone masses to individual volumes in an image pixel using the physical densities of the components and the know area of the pixel.
* Total body water measurement using standard deuterium dilution methods. The primary measure is total body water in liters.
* Body volume measurement using air displacement plethsymography. The primary measure is volume in liters.
* Whole body 3D optical surface scans. The primary measures mesh points that make up a point cloud of the surface of the body. Approximately 500,000 mesh points are used and placed on the surface of the participants body image. The variation of the location of these mesh points can be described using Principal Component Analysis (PCA). In addition, the 3D optical scans can be used to measure the thickness of the body along the path of each X-ray that goes through the body resulting in a tissue thickness for each DXA image pixel.
* Bioelectrical impedance analysis (BIA). The primary measure is percent body fat, and total body water.
* Physical anthropometry. The primary measure is waist circumference.

Eligibility Criteria:
Inclusion Criteria:

* ambulatory
* tolerate lying on their back on a table for 20 minutes
* less than 250 lbs
* tolerate standing and holding still for 1 minute

Exclusion Criteria:

* cannot stand for several minutes
* cannot lie down on a table for 10 minutes
* over 250 lbs
Integrated Care Pathway for Youth Depression

Major Depressive Disorder in adolescence is prevalent and debilitating. Our group aims to improve treatment response through the use of an Integrated Care Pathway (ICP) based on a high quality Clinical Practice Guideline and measurement-based care (MBC; where periodic symptom scale scores are used to make treatment decisions). We propose a controlled clinical trial comparing ICP to treatment-as-usual (TAU) across two sites.

Background: There is a gap between what is known from the evidence about the treatment of adolescent depression and what is practiced. Moreover, while there is evidence that measurement-based care can improve outcomes for adults with various mental health conditions, there is limited information on this framework in adolescent depression.

Objective: Our study aims to enhance the implementation of evidence-based care (using the NICE Clinical Practice Guidelines as a template) combined wtih measurement-based care through the use of an Integrated Care Pathway (ICP) in adolescents with depression.

Hypothesis: As this is a pilot study, our hypotheses centre around feasibility. We hypothesize that: (1) we will recruit at least 30 participants to the ICP treatment arm and 30 participants at the "treatment-as-usual" arm at a different site (2) that baseline measures will be fully completed by 95% of adolescents recruited, (3) that baseline measures will take 2 hours to complete for adolescents and 1 hour to complete for caregivers, (4) that a mean of 90% of the key aspects of the treatment protocol are followed in the ICP group (5) that 80% of participants recruited will complete measures at the end of the 20-week interval and that (6) 90% of the youth, caregivers and clinicians who partake int eh study will attend a focus group to provide qualitative feedback on their experience.

Design: This is a non-randomized controlled clinical trial. Randomizing at the individual level is not possible - the intervention is implemented at the clinic level; so the effect of the intervention on one youth within a clinic would influence the care of other youth at the clinic.

Sampling: Participants are recruited from psychiatric clinics at 2 sites. Each site will recruit to their respective treatment arm.

Eligibility Criteria:
Inclusion Criteria:

* Psychiatrist's impression is that depression is a primary psychiatric. concern
* 14-18 years old.
* DSM-5 criteria for Major Depressive Disorder or Persistent Depressive Disorder as per the Diagnostic Interview for Affective Symptoms for Children (DIAS-C19).
* Speak, read and write English at a grade 6 level.

Exclusion Criteria:

* Threshold psychotic symptoms.
* Bipolar disorder.
* Moderate-to-severe substance use disorder.
* Autistic spectrum disorder or intellectual disability.
* Eating disorder.
* Suicide-related behaviours requiring acute intervention.
Improving Depression Care for Elders: Coordinating Center

Purpose: To determine the effectiveness of the Improving Mood-Promoting Access to Collaborative Treatment(IMPACT) collaborative care management program for late-life depression.

This study tested an organized method of delivering care for late life depression in primary care. Specifically, the investigators evaluated the effectiveness of this intervention as compared to 'care as usual'. The investigators studied the effect of the intervention on clinical outcomes such as depressive symptoms, functional status, health related quality of life. They also determined the cost-effectiveness of the intervention compared to care as usual.

Eligibility Criteria:
Inclusion Criteria:

* Major depression or dysthymia as diagnosed by a structured diagnostic interview.
* Patient plans to receive primary care at the study clinic for the next year.

Exclusion Criteria:

* Age under 60.
* Current symptoms or history of psychosis or mania as determined by structured diagnostic interview.
* Cognitive impairment as defined by a score less than 23 on a Mini Mental Status Examination.
* Terminal illness - defined as having a life expectancy of less than 6 months.
* Active alcohol abuse as determined by a screening interview.
* High suicide risk as determined by current plan for suicide or a history of more than 3 prior suicide attempts in the past 10 years.